comparemela.com

Latest Breaking News On - Iwcll - Page 1 : comparemela.com

Matching-Adjusted Analysis Shows Acalabrutinib/Obinutuzumab Offers PFS Benefit Vs Zanubrutinib in CLL/SLL Without 17p Deletions

Patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic leukemia without 17p deletions experienced superior efficacy following treatment with acalabrutinib plus obinutuzumab compared with zanubrutinib monotherapy.

Retrospective Analysis Sheds Light on Mutations Linked With BTK Inhibitor Resistance in CLL

Patients with chronic lymphocytic leukemia who experience disease progression during treatment with either covalent or noncovalent BTK inhibitors displayed a higher frequency of BTK mutations in L528W as well as RAS/RAF/MAPK pathway alterations, indicating that these alterations may play a role in the development of BTK inhibitor resistance.

Venetoclax and Rituximab Combination Maintains Survival Benefit in Relapsed/Refractory CLL

Patients with relapsed/refractory chronic lymphocytic leukemia achieved sustained progression-free survival and overall survival benefit after treatment with fixed-duration venetoclax plus rituximab vs bendamustine plus rituximab, according to data from the phase 3 MURANO trial.

Continued Maintenance With Obinutuzumab Plus Acalabrutinib/Venetoclax Boosts uMRD Rate in R/R CLL

The undetectable minimal residual disease ate achieved with bendamustine followed by obinutuzumab, acalabrutinib, and venetoclax increased as the regimen was continued as maintenance treatment in patients with relapsed or refractory chronic lymphocytic leukemia.

Pirtobrutinib Maintains Efficacy and Decreases BTK C481 Clones Despite Acquired Resistance Mutations in CLL

Patients with chronic lymphoctyic leukemia treated with pirtobrutinib monotherapy experienced comparable objective response rates regardless of acquired BTK mutation and a decrease or clearance of BTK cysteine 481 clones despite the emergence of non-C481 clones or other less common mutations during or near the time of progression.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.